Pictet Asset Management Ltd. Buys 21,900 Shares of Genomic Health, Inc. (NASDAQ:GHDX)

Pictet Asset Management Ltd. increased its stake in Genomic Health, Inc. (NASDAQ:GHDX) by 10.2% in the third quarter, HoldingsChannel reports. The fund owned 237,437 shares of the medical research company’s stock after purchasing an additional 21,900 shares during the period. Pictet Asset Management Ltd.’s holdings in Genomic Health were worth $16,103,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in GHDX. Nisa Investment Advisors LLC lifted its stake in shares of Genomic Health by 390.0% in the 3rd quarter. Nisa Investment Advisors LLC now owns 490 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 390 shares during the last quarter. AdvisorNet Financial Inc bought a new stake in shares of Genomic Health in the 3rd quarter valued at about $34,000. Tower Research Capital LLC TRC lifted its stake in shares of Genomic Health by 69.8% in the 3rd quarter. Tower Research Capital LLC TRC now owns 518 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 213 shares during the last quarter. LS Investment Advisors LLC bought a new stake in shares of Genomic Health in the 3rd quarter valued at about $48,000. Finally, Point72 Asset Management L.P. bought a new stake in shares of Genomic Health in the 2nd quarter valued at about $93,000. 93.87% of the stock is owned by institutional investors.

In other Genomic Health news, insider Laura Leber sold 13,183 shares of the company’s stock in a transaction that occurred on Thursday, October 17th. The stock was sold at an average price of $70.94, for a total transaction of $935,202.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kimberly J. Popovits sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $72.53, for a total value of $725,300.00. The disclosure for this sale can be found here. Insiders have sold a total of 114,743 shares of company stock valued at $8,125,643 in the last ninety days. 31.30% of the stock is currently owned by corporate insiders.

GHDX opened at $63.44 on Monday. The business has a 50 day simple moving average of $66.18 and a two-hundred day simple moving average of $64.41. The firm has a market capitalization of $2.38 billion, a price-to-earnings ratio of 60.42 and a beta of 0.90. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.96 and a quick ratio of 5.96. Genomic Health, Inc. has a one year low of $50.77 and a one year high of $90.18.

Genomic Health (NASDAQ:GHDX) last released its quarterly earnings results on Monday, November 11th. The medical research company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.11. Genomic Health had a return on equity of 19.62% and a net margin of 12.81%. As a group, sell-side analysts expect that Genomic Health, Inc. will post 1.58 EPS for the current fiscal year.

GHDX has been the subject of a number of recent research reports. BidaskClub raised Genomic Health from a “sell” rating to a “hold” rating in a research note on Tuesday, November 5th. ValuEngine lowered Genomic Health from a “buy” rating to a “hold” rating in a research note on Tuesday, September 10th. Ten equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Genomic Health currently has a consensus rating of “Hold” and a consensus target price of $69.86.

Genomic Health Profile

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Featured Story: What is a growth and income fund?

Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health, Inc. (NASDAQ:GHDX).

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.